ABUS vs WY · P/E 5.4, rev $6.2M vs P/E 43, rev $7.12B
Arbutus Biopharma Corp (ABUS) versus Weyerhaeuser Company (WY) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Weyerhaeuser Company (WY) is a reit - specialty company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported WY revenue for 2024-12-31 was $7.12B. Net income was $396.0M. Revenue was down 7.2% from 2023-12-31 to 2024-12-31. WY currently screens at market cap $17.54B and trailing P/E 43.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. WY currently screens at market cap $17.54B and trailing P/E 43.4.
Not investment advice. Open the ABUS and WY stock pages for the full models.
Not investment advice.